Publications by authors named "Maurine D Miner"

Claim this Profile
S
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.
Kelly E Seaton, Carmen A Paez, Chenchen Yu, Shelly T Karuna, Theresa Gamble, Maurine D Miner

Lancet HIV· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.
Leigh H Fisher, Erica Lazarus, Chenchen Yu, Zoe Moodie, Daniel J Stieh, Maurine D Miner

PLOS Glob Public Health· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.
Nigel Garrett, Asa Tapley, Aaron Hudson, Sufia Dadabhai, Bo Zhang, Maurine D Miner

EClinicalMedicine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, Yunda Huang, Carmen A Paez, Maurine D Miner

Lancet HIV· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.
Vimla Naicker, Fatima Laher, Linda-Gail Bekker, Kelly E Seaton, Mary Allen, Maurine D Miner

PLOS Glob Public Health· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local Power: The Role of Tissue-Resident Immunity in Human Genital Herpes Simplex Virus Reactivation.
Jia Zhu, Maurine D Miner

Viruses· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Maurine D Miner

PLoS Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial.
Maurine D Miner, Allan deCamp, Nicole Grunenberg, Stephen C De Rosa, Andrew Fiore-Gartland

EBioMedicine· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Magdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, Chenchen Yu, Theresa Gamble, Maurine D Miner

Lancet HIV· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region.
Shelly Karuna, Jorge A Gallardo-Cartagena, Deborah Theodore, Portia Hunidzarira, Juan Montenegro-Idrogo, Maurine D Miner

J Glob Health· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
Gregory J Wilson, Benigno Rodriguez, Shuying Sue Li, Mary Allen, Ian Frank, Maurine D Miner

Vaccine· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel.
Maurine D Miner, Mark Hatherill, Vidya Mave, Glenda E Gray, Sharon Nachman

Lancet HIV· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Asymptomatic Carriage With the Omicron Variant in South Africa.
Nigel Garrett, Asa Tapley, Jessica Andriesen, Ishen Seocharan, Leigh H Fisher, Maurine D Miner

Clin Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating clinical trial development in vaccinology: COVID-19 and beyond.
Lawrence Corey, Maurine D Miner

Curr Opin Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.
Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R Walsh, Ian Frank, Maurine D Miner

PLoS Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017.
Maurine D Miner, Linda-Gail Bekker, Tamara Kredo, Niresh Bhagwandin, Lawrence Corey

Trials· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broadly neutralizing monoclonal antibodies for HIV prevention.
Maurine D Miner, Lawrence Corey, David Montefiori

J Int AIDS Soc· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays.
Anton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, Maurine D Miner, Yixuan J Hou

J Clin Microbiol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
Yunda Huang, Kelly E Seaton, Martin Casapia, Laura Polakowski, Stephen C De Rosa, Maurine D Miner

Vaccine· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
Srilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, Philip Andrew, Erika Rudnicki, Maurine D Miner

J Acquir Immune Defic Syndr· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.
Nyaradzo M Mgodi, Simbarashe Takuva, Srilatha Edupuganti, Shelly Karuna, Philip Andrew, Maurine D Miner

J Acquir Immune Defic Syndr· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Mina C Hosseinipour, Craig Innes, Sarita Naidoo, Philipp Mann, Julia Hutter, Maurine D Miner

Clin Infect Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Zoe Moodie, Stephen R Walsh, Fatima Laher, Lucas Maganga, Michael E Herce, Maurine D Miner

PLoS Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in -uninfected adolescents in Cape Town, South Africa.
Linda-Gail Bekker, One Dintwe, Andrew Fiore-Gartland, Keren Middelkoop, Julia Hutter, Maurine D Miner

EClinicalMedicine· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterium tuberculosis strains lacking surface lipid phthiocerol dimycocerosate are susceptible to killing by an early innate host response.
Tracey A Day, John E Mittler, Molly R Nixon, Cullen Thompson, Maurine D Miner

Infect Immun· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis